Neck News and Research

RSS

Two leading authorities partner to write and edit Stroke Prevention, Treatment and Rehabilitation

Stroke prevention, treatment and rehabilitation have come a long way in the time since Neurologist Dr. David Spence of Western University began treating patients. "My first day on call, I was paged to the emergency department for a patient with a stroke. When I answered the page, from the cafeteria, I was told to go ahead and finish my dinner. There was nothing that could be done for him."

4 Apr 2012

Nuvilex realizes important role for Cell-in-a-Box technology

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions through acquisition of SG Austria assets, realizes the important role for Cell-in-a-Box technology and aims to bring to light its use in the production of therapeutic antibodies for clinically important diseases.

4 Apr 2012

Nine physician organizations identify specific tests or procedures that may be unnecessary

Nine leading physician specialty societies have identified specific tests or procedures that they say are commonly used but not always necessary in their respective fields. Patient advocates are calling the move a significant step toward improving the quality and safety of health care.

4 Apr 2012

Combination of carboplatin, paclitaxel and RT3D shows promise against head and neck cancer

A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research.

4 Apr 2012

Viewpoints: Shouldering the health costs of the 'irresponsible'; Learning from the parallels between Obamacare and the 'war on terror'

The central idea of the Patient Protection and Affordable Care Act - the formal name of the Obamacare law - emphasized in the hearings is to spread the cost of health care to ever-larger pools of Americans. In particular, to those who pay low health insurance premiums, the young who choose to have no insurance and the healthy.

4 Apr 2012

Navidea announces FDA extension of Lymphoseek PDUFA date by three months

Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.

4 Apr 2012

CYP1B1 protein may be a potential target for intervention in head and neck cancer

Squamous cell carcinoma of the head and neck-which typically arises from thin, flat cells that line moist surfaces inside the mouth, nose and throat-is the sixth most common type of cancer worldwide, and it has a relatively low five-year survival rate and a high recurrence rate.

2 Apr 2012

Safe method for destroying cancer cells using death cap mushroom poison

The mere thought of an identification error sends a chill down the spine of any mushroom lover: The death cap mushroom (Amanita phalloides), which resembles the common white button mushroom, contains one of the most deadly poisons found in nature, α-amanitin.

2 Apr 2012

Enrollment complete in Oncolytics REOLYSIN combination trial for head and neck cancers

Oncolytics Biotech Inc. announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).

2 Apr 2012

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

RT3D may boost effects of two standard chemotherapy drugs in head and neck cancer patients

2 Apr 2012

Survivin protein could be a useful tool in understanding pancreatic cancer

Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis that treatment is unlikely to provide significantly life-extending benefits. For patients diagnosed with localized pancreatic cancer, the five-year survival rate remains barely above 20 percent, according to the National Cancer Institute.

2 Apr 2012

Aurora-A protein plays an important role in head and neck cancer

Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments. The findings will be reported at the AACR Annual Meeting 2012 on Sunday, April 1.

2 Apr 2012

Long delays for persistent pain management

An article in the Australian Medical Journal reveals that taxpayers are paying $34 billion a year to treat persistent pain. Pain specialist Dr Timothy Semple, and president of the Australian Pain Society, told the Herald Sun chronic back pain, arthritis, nerve injuries and people who needed care after surviving cancer made up significant numbers.

1 Apr 2012

Johns Hopkins Hospital's new home to open on May 1

The Johns Hopkins Hospital's new home, set to open on May 1, will redefine the very essence of the hospital experience, and cutting-edge technology designed to improve care, streamline workflow and encourage efficiencies will play a central role.

31 Mar 2012

ASA recognizes Doctors' Day 2012

The American Society of Anesthesiologists (ASA) today joins Americans across the nation to recognize Doctors' Day 2012, an observance to celebrate the contributions of physicians.

31 Mar 2012

Elective endovascular aneurysm repair benefits men more than women

A study published in the April issue of Journal of Vascular Surgery reports that women derive less benefit than men from elective endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA's). The research was done at The Vascular Group, The Institute for Vascular Health and Disease, Albany Medical College, The Center for Vascular Awareness Inc., in Albany, NY.

31 Mar 2012

HPV-related head and neck cancer on the rise among middle-aged white men

Research led by Lauren Cole, a public health graduate student, and Dr. Edward Peters, Associate Professor of Public Health and Director of the Epidemiology Program at LSU Health Sciences Center New Orleans, reports that the incidence of head and neck cancer has risen at sites associated with Human Papilloma Virus (HPV) infection, with the greatest increase among middle-aged white men.

30 Mar 2012

Elekta receives EU CE marking for Connexion modular couchtop

Elekta's Connexion modular couchtop is CE marked and successfully released for sale in the European Union. Connexion meets the clinic's need to tailor patient set-up to accommodate the unique therapy requirements of the individual patient.

From Elekta 29 Mar 2012

One-side parathyroid surgery has poorer long-term outcomes

Dr James Norman, MD and his partners at the Norman Parathyroid Center have published a landmark study in this week's Journal of the American College of Surgeons describing how the operation they developed and advocated for more than 19 years has significantly poorer long-term outcomes. The unilateral or "one-side" parathyroid surgical procedure to remove parathyroid tumors from patients suffering from hyperparathyroidism is a dramatic change from the large neck operation that it replaced.

29 Mar 2012

Neck News and Research

Two leading authorities partner to write and edit Stroke Prevention, Treatment and Rehabilitation

Nuvilex realizes important role for Cell-in-a-Box technology

Nine physician organizations identify specific tests or procedures that may be unnecessary

Combination of carboplatin, paclitaxel and RT3D shows promise against head and neck cancer

Viewpoints: Shouldering the health costs of the 'irresponsible'; Learning from the parallels between Obamacare and the 'war on terror'

Navidea announces FDA extension of Lymphoseek PDUFA date by three months

CYP1B1 protein may be a potential target for intervention in head and neck cancer

Safe method for destroying cancer cells using death cap mushroom poison

Enrollment complete in Oncolytics REOLYSIN combination trial for head and neck cancers

Clinical data for cabozantinib to be presented at ASCO annual meeting

RT3D may boost effects of two standard chemotherapy drugs in head and neck cancer patients

Survivin protein could be a useful tool in understanding pancreatic cancer

Aurora-A protein plays an important role in head and neck cancer

Long delays for persistent pain management

Johns Hopkins Hospital's new home to open on May 1

ASA recognizes Doctors' Day 2012

Elective endovascular aneurysm repair benefits men more than women

HPV-related head and neck cancer on the rise among middle-aged white men

Elekta receives EU CE marking for Connexion modular couchtop

One-side parathyroid surgery has poorer long-term outcomes

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News